Hohimer Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Hohimer Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$347K	Buy	11,033 +38	+0.3%	+$1.12K	0.03%	258
2026 Q1	$272K	Sell	10,995 -5,436	-33%	-$130K	0.03%	246
2025 Q4	$384K	Buy	16,431 +18	+0.1%	+$401	0.05%	202
2025 Q3	$323K	Buy	16,413 +4,439	+37%	+$91.3K	0.05%	214
2025 Q2	$260K	Sell	11,974 -6,096	-34%	-$144K	0.05%	197
2025 Q1	$438K	Buy	18,070 +629	+4%	+$14.2K	0.09%	170
2024 Q4	$364K	Buy	17,441 +898	+5%	+$19.3K	0.07%	163
2024 Q3	$329K	Buy	+16,543	New	+$307K	0.07%	161

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hohimer Wealth Management's CPRX Position: Q2 2026 in Review

Hohimer Wealth Management increased its Catalyst Pharmaceutical (CPRX) stake by 0.35% in Q2 2026, buying an estimated $1.12K and bringing the position to 11,033 shares worth $347K. The position accounts for 0.03% of the portfolio, ranked #258.

Hohimer Wealth Management first reported a position in CPRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $438K in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Hohimer Wealth Management held 11,033 shares of Catalyst Pharmaceutical worth $347K as of Q2 2026.
Hohimer Wealth Management bought 38 Catalyst Pharmaceutical shares in Q2 2026, an estimated $1.12K.
Catalyst Pharmaceutical made up 0.03% of Hohimer Wealth Management's portfolio in Q2 2026, its #258 holding.
Hohimer Wealth Management first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 8 quarters since.
Hohimer Wealth Management's Catalyst Pharmaceutical position peaked at $438K in Q1 2025.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Hohimer Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.